
Genetic analysis finds 125 loci shared by insomnia and CRP, with Mendelian randomization favoring an effect from insomnia liability to inflammation.
The Food and Drug Administration said its authority over compounding pharmacies is limited and needs to be strengthened in the wake of a multistate meningitis outbreak caused by tainted steroid injections produced by a pharmacy in Massachusetts.
The FDA has come under scrutiny for its oversight of the New England Compounding Center, the Framingham, Mass.-based compounding pharmacy that is responsible for distributing contaminated vials of preservative-free methylprednisolone acetate.
Read the full story:
Source: ModernHealthcare.com





